找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Nanomedicines for Effective Cancer Therapy; Hitoshi Kasai,Hiroshi Uji-i,Johan Hofkens Book 2024 The Editor(s) (if applicable) and The Auth

[復(fù)制鏈接]
樓主: Forestall
31#
發(fā)表于 2025-3-26 23:09:01 | 只看該作者
Targeted Drug Delivery for Cancer Therapy Using Functionalized Nanocarrierse therapies are based on passive accumulation in tumor tissues via enhanced permeability of tumor vasculature, namely the enhanced permeability and retention effect (EPR effect). However, the efficacy of EPR-based drug delivery is controversial because liposomal doxorubicin potentially has an insuf
32#
發(fā)表于 2025-3-27 02:24:08 | 只看該作者
Cancer Photo Therapies that Target Mitochondriapeutic molecule of choice to act where it is needed and for the required time. Cancer photo therapy typically involves photochemical reactions induced by light irradiation to cause cell death. Over the past few decades, mitochondria have attracted considerable attention in the field of therapy. The
33#
發(fā)表于 2025-3-27 05:54:26 | 只看該作者
34#
發(fā)表于 2025-3-27 12:23:45 | 只看該作者
35#
發(fā)表于 2025-3-27 13:43:27 | 只看該作者
36#
發(fā)表于 2025-3-27 19:25:00 | 只看該作者
Cell Membrane Mimetic Amphiphilic Phospholipid Polymers for Advanced Nanomedicinee, we introduce phospholipid polymers, whose molecular design is based on the surface structure of cell membranes, and their role in drug formulation. These phospholipid polymers are amphiphilic, can substantially enhance the solubility of drugs in aqueous media, and can permeate membranes through m
37#
發(fā)表于 2025-3-27 23:17:52 | 只看該作者
38#
發(fā)表于 2025-3-28 04:45:33 | 只看該作者
39#
發(fā)表于 2025-3-28 08:14:50 | 只看該作者
3D Tumor Models—Nanomedicine in the Third Dimensionnced efficacy and reduced side effects has marked a significant step forward in cancer research. However, the promising results observed in preclinical studies show low translatability into the clinic, due to a lack of adequate preclinical models that faithfully mimic the complex tumor microenvironm
40#
發(fā)表于 2025-3-28 11:55:16 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 14:26
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
佛坪县| 蕉岭县| 新兴县| 山丹县| 咸阳市| 青河县| 毕节市| 勃利县| 台中县| 仁怀市| 米林县| 玛曲县| 涟源市| 河西区| 文化| 新建县| 红桥区| 万安县| 平湖市| 大兴区| 封丘县| 同心县| 眉山市| 宝丰县| 贞丰县| 聂拉木县| 萍乡市| 衢州市| 奇台县| 舞阳县| 新宁县| 崇文区| 郴州市| 巴里| 泸水县| 滨海县| 双鸭山市| 镇雄县| 邯郸市| 赤壁市| 岑巩县|